{
    "body": "Describe the mechanism of action of Bezlotoxumab?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27905086", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27753689", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25385797", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25486992", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24821719", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27527088", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25451052", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27757389"
    ], 
    "ideal_answer": [
        "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin B (TcdB). It is used for prevention of  recurrent C. difficile infections."
    ], 
    "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020228"
    ], 
    "type": "summary", 
    "id": "588fa24fed9bbee70d000005", 
    "snippets": [
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 117, 
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin B developed by Merck&Co. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27905086", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 86, 
            "offsetInEndSection": 320, 
            "text": "Circulating neutralizing antitoxin antibodies are protective in C. difficile infection (CDI), as demonstrated, in part, by the protective effects of actoxumab and bezlotoxumab, which bind to and neutralize TcdA and TcdB, respectively.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25385797", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 155, 
            "offsetInEndSection": 295, 
            "text": "Actoxumab and bezlotoxumab are human monoclonal antibodies that neutralize the cytotoxic/cytopathic effects of TcdA and TcdB, respectively. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451052", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1242, 
            "offsetInEndSection": 1542, 
            "text": "We compared the bezlotoxumab epitopes in the TcdB receptor binding domain across known TcdB sequences and found that key substitutions within the bezlotoxumab epitopes correlated with the relative differences in potencies of bezlotoxumab against TcdB of some strains, including ribotypes 027 and 078.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451052", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 135, 
            "text": "Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24821719", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 245, 
            "offsetInEndSection": 578, 
            "text": "A combination of the anti-TcdA antibody actoxumab and the anti-TcdB antibody bezlotoxumab is currently under development for the prevention of recurrent C. difficile infections. We demonstrate here through various biophysical approaches that bezlotoxumab binds to specific regions within the N-terminal half of the TcdB CROP domain. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24821719", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 999, 
            "offsetInEndSection": 1411, 
            "text": "We also show that bezlotoxumab neutralizes TcdB by blocking binding of TcdB to mammalian cells. Overall, our data are consistent with a model wherein a single molecule of bezlotoxumab neutralizes TcdB by binding via its two Fab regions to two epitopes within the N-terminal half of the TcdB CROP domain, partially blocking the carbohydrate binding pockets of the toxin and preventing toxin binding to host cells.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24821719", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1235, 
            "offsetInEndSection": 1535, 
            "text": "We compared the bezlotoxumab epitopes in the TcdB receptor binding domain across known TcdB sequences and found that key substitutions within the bezlotoxumab epitopes correlated with the relative differences in potencies of bezlotoxumab against TcdB of some strains, including ribotypes 027 and 078.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451052", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 994, 
            "offsetInEndSection": 1089, 
            "text": "We also show that bezlotoxumab neutralizes TcdB by blocking binding of TcdB to mammalian cells.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24821719", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 118, 
            "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin B developed by Merck & Co.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27905086", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 154, 
            "offsetInEndSection": 293, 
            "text": "Actoxumab and bezlotoxumab are human monoclonal antibodies that neutralize the cytotoxic/cytopathic effects of TcdA and TcdB, respectively.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451052", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 522, 
            "offsetInEndSection": 674, 
            "text": "The monoclonal antitoxin antibodies actoxumab (anti-TcdA) and bezlotoxumab (anti-TcdB) are currently in development for the prevention of recurrent CDI.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27527088", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 485, 
            "offsetInEndSection": 708, 
            "text": "A combination of human monoclonal antibodies, actoxumab and bezlotoxumab, directed against TcdA and TcdB, respectively, has been shown to decrease the rate of recurrence in patients treated with standard-of-care antibiotics", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25486992", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 86, 
            "offsetInEndSection": 319, 
            "text": "Circulating neutralizing antitoxin antibodies are protective in C. difficile infection (CDI), as demonstrated, in part, by the protective effects of actoxumab and bezlotoxumab, which bind to and neutralize TcdA and TcdB, respectively", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25385797", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 423, 
            "offsetInEndSection": 577, 
            "text": "We demonstrate here through various biophysical approaches that bezlotoxumab binds to specific regions within the N-terminal half of the TcdB CROP domain.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24821719", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 578, 
            "offsetInEndSection": 721, 
            "text": "Based on this information, we solved the x-ray structure of the N-terminal half of the TcdB CROP domain bound to Fab fragments of bezlotoxumab.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24821719", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 722, 
            "offsetInEndSection": 998, 
            "text": "The structure reveals that the TcdB CROP domain adopts a \u03b2-solenoid fold consisting of long and short repeats and that bezlotoxumab binds to two homologous sites within the CROP domain, partially occluding two of the four putative carbohydrate binding pockets located in TcdB.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24821719", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1095, 
            "offsetInEndSection": 1512, 
            "text": "Overall, our data are consistent with a model wherein a single molecule of bezlotoxumab neutralizes TcdB by binding via its two Fab regions to two epitopes within the N-terminal half of the TcdB CROP domain, partially blocking the carbohydrate binding pockets of the toxin and preventing toxin binding to host cells. <CopyrightInformation>\u00a9 2014 by The American Society for Biochemistry and Molecular Biology, Inc.</C", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24821719", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 136, 
            "text": "Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24821719", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 999, 
            "offsetInEndSection": 1094, 
            "text": "We also show that bezlotoxumab neutralizes TcdB by blocking binding of TcdB to mammalian cells.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24821719", 
            "endSection": "abstract"
        }
    ]
}